The current administration’s Executive Order on Ending Crime and Disorder on America’s streets is yet another direct attack on science and basic human rights.
Treatment Action Group (TAG) opposes in the strongest possible terms the suspension of at least 22 TB research awards by the National Institutes of Health (NIH) following a May 2025 White House executive order banning “gain-of-function” research.
TAG is organizing this webinar on July 29 for community organizations and advocates to raise awareness about the HCV Elimination bill, and prepare them to meet and engage with their Senators during the August recess in their district offices or Town Hall meetings.
TAG was among thirteen organizations that cosponsored this Congressional briefing held on July 9, 2025. Briefing materials and presentations are available for download.
Treatment Action Group (TAG) is proud to announce Dr. Richard Lynn — scientist, activist, philanthropist, and founding member of TAG — as the third and final honoree for the 2025 Research in Action Awards (RIAA), to be held on October 20 at the Angel Orensanz Foundation in New York City.
Treatment Action Group (TAG) is proud to announce that Gloria Reuben — award-winning actress, singer, author, and longtime HIV/AIDS advocate — will be honored at the 2025 Research in Action Awards (RIAA) for her unwavering dedication to public health, activism, and the arts.
Treatment Action Group (TAG) is proud to announce that Tom Postilio and Mickey Conlon — renowned philanthropists, internationally acclaimed real estate leaders, and dedicated advocates for public health — will serve as Event Chairs for the 2025 Research in Action Awards (RIAA).
Treatment Action Group (TAG) is issuing an urgent call to protect the integrity of biomedical research and public health.
Treatment Action Group (TAG) decries the vicious and inchoate attacks on HHS since the advent of the new administration, which have escalated significantly over the past week.
This policy brief describes the crucial role NIH plays in supporting research on new products to prevent, diagnose, and cure TB. This research is especially important at a time when new forms of drug resistance are emerging globally, and rates of TB are rising in the U.S. With continued and increased funding, NIH can protect Americans from the growing threat of TB at home and abroad.